0.00Open0.05Pre Close0 Volume0 Open Interest25.00Strike Price0.00Turnover1064.72%IV12.89%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-7DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0550Delta0.0500Gamma443.80Leverage Ratio-3.2590Theta0.0000Rho24.42Eff Leverage0.0002Vega
Organon & Co Stock Discussion
At the close in NYSE, the Dow Jones Industrial Average fell 0.45%, while the S&P 500 index lost 0.42%, and the NASDAQ Composite index lost 0.79%.
The best performers of the session on the Dow Jones Industrial Average were Amgen Inc ( $Amgen(AMGN.US)$ ), which rose 3.11% or 7.86 points t...
Gap Ups
1. $Novo-Nordisk A/S(NVO.US)$ - up 13.4%
2. $Eli Lilly and Co(LLY.US)$ - up 10.5%
3. $James Hardie Industries(JHX.US)$ - up 10.1%
4. $New York Times(NYT.US)$ - up 3.3%
5. $POSCO(PKX.US)$ - up 2.9%
6. $Fox Corp-B(FOX.US)$ - up 2.8%
7. $Fox Corp-A(FOXA.US)$ - up 2.8%
8. $West Pharmaceutical Services(WST.US)$ - up 2.5...
even right now
Loop Capital analyst Charles Park initiated coverage of $Micron Technology(MU.US)$ with a Buy rating and $70 price target. The analyst expects DRAM fundamentals to bottom in the first half of 2023 and notes that the shares "typically bottoming a couple of quarters ahead."
AppLovin Initiated With an Outperform at Wedbush
Wedbush analyst Nick McKay initiated coverage of $Applovin(APP.US)$ with an O...
Darė already has FDA approval for Xaciato with which they announced a partnership with $Organon & Co(OGN.US)$ and expect revenues to begin generating in Q4 2022.
This is a promising bio for the patient investor IMO...
No comment yet